The stem cell market and policy options: A call for clarity

Amy Zarzeczny, Harold Atkins, Judy Illes, Jonathan Kimmelman, Zubin Master, Julie M. Robillard, Jeremy Snyder, Leigh Turner, Patricia J. Zettler, Timothy Caulfield

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


The field of regenerative medicine is widely viewed as having the potential to improve treatment options for a broad range of conditions. Stem cell research in particular has been celebrated for its considerable clinical promise. Although measured enthusiasm surrounding this area of research is warranted, it must be balanced by patience and set in the context of a long-term perspective that is cognizant of the many steps required to bring safe and efficacious therapies to market. Creating therapeutic applications of stem cell technologies is an intricate process involving complex biology. It will require careful scientific investigation and evaluation under responsible ethical frameworks and regulatory standards in order to safely maximize their potential. Alongside the many promising avenues of responsible research currently underway in countries throughout the world, a global market has emerged where a wide range of putative stem cell-based interventions are sold on a direct-to-consumer basis and marketed over the internet.1,2,3,4

Original languageEnglish (US)
Pages (from-to)743-758
Number of pages16
JournalJournal of Law and the Biosciences
Issue number3
StatePublished - Sep 18 2018

Bibliographical note

Publisher Copyright:
© The Author(s) 2018.


  • Patient and public engagement
  • Policy
  • Regulation
  • Stem cell research
  • Unproven stem cell interventions


Dive into the research topics of 'The stem cell market and policy options: A call for clarity'. Together they form a unique fingerprint.

Cite this